Congenital hyperinsulinism
- PMID: 20550977
- DOI: 10.1016/j.earlhumdev.2010.05.003
Congenital hyperinsulinism
Abstract
Congenital hyperinsulinism (CHI or HI) is a condition leading to recurrent hypoglycemia due to an inappropriate insulin secretion by the pancreatic islet beta cells. HI has two main characteristics: a high glucose requirement to correct hypoglycemia and a responsiveness of hypoglycemia to exogenous glucagon. HI is usually isolated but may be rarely part of a genetic syndrome (e.g. Beckwith-Wiedemann syndrome, Sotos syndrome etc.). The severity of HI is evaluated by the glucose administration rate required to maintain normal glycemia and the responsiveness to medical treatment. Neonatal onset HI is usually severe while late onset and syndromic HI are generally responsive to a medical treatment. Glycemia must be maintained within normal ranges to avoid brain damages, initially with glucose administration and glucagon infusion then, once the diagnosis is set, with specific HI treatment. Oral diazoxide is a first line treatment. In case of unresponsiveness to this treatment, somatostatin analogues and calcium antagonists may be added, and further investigations are required for the putative histological diagnosis: pancreatic (18)F-fluoro-L-DOPA PET-CT and molecular analysis. Indeed, focal forms consist of a focal adenomatous hyperplasia of islet cells, and will be cured after a partial pancreatectomy. Diffuse HI involves all the pancreatic beta cells of the whole pancreas. Diffuse HI resistant to medical treatment (octreotide, diazoxide, calcium antagonists and continuous feeding) may require subtotal pancreatectomy which post-operative outcome is unpredictable. The genetics of focal islet-cells hyperplasia associates a paternally inherited mutation of the ABCC8 or the KCNJ11 genes, with a loss of the maternal allele specifically in the hyperplasic islet cells. The genetics of diffuse isolated HI is heterogeneous and may be recessively inherited (ABCC8 and KCNJ11) or dominantly inherited (ABCC8, KCNJ11, GCK, GLUD1, SLC16A1, HNF4A and HADH). Syndromic HI are always diffuse form and the genetics depend on the syndrome. Except for HI due to potassium channel defect (ABCC8 and KCNJ11), most of these HI are sensitive to diazoxide. The main points sum up the management of HI: i) prevention of brain damages by normalizing glycemia and ii) screening for focal HI as they may be definitively cured after a limited pancreatectomy.
2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography.Diabetes. 2006 Jan;55(1):13-8. Diabetes. 2006. PMID: 16380471
-
Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.Horm Res. 2008;70(1):59-64. doi: 10.1159/000129680. Epub 2008 May 21. Horm Res. 2008. PMID: 18493152 Clinical Trial.
-
Identification of two novel frameshift mutations in the KCNJ11 gene in two Italian patients affected by Congenital Hyperinsulinism of Infancy.Exp Mol Pathol. 2007 Aug;83(1):59-64. doi: 10.1016/j.yexmp.2006.11.006. Epub 2007 Jan 17. Exp Mol Pathol. 2007. PMID: 17316607
-
Congenital hyperinsulinism: current trends in diagnosis and therapy.Orphanet J Rare Dis. 2011 Oct 3;6:63. doi: 10.1186/1750-1172-6-63. Orphanet J Rare Dis. 2011. PMID: 21967988 Free PMC article. Review.
-
Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates.Nat Clin Pract Endocrinol Metab. 2007 Jan;3(1):57-68. doi: 10.1038/ncpendmet0368. Nat Clin Pract Endocrinol Metab. 2007. PMID: 17179930 Review.
Cited by
-
Clinical management of diazoxide-unresponsive congenital hyperinsulinism: A single-center experience.Clin Pediatr Endocrinol. 2024;33(3):187-194. doi: 10.1297/cpe.2024-0004. Epub 2024 Jun 3. Clin Pediatr Endocrinol. 2024. PMID: 38993725 Free PMC article.
-
Pancreatic head resection preserving the main pancreatic duct for congenital hyperinsulinism of infancy.Pediatr Surg Int. 2012 Sep;28(9):935-7. doi: 10.1007/s00383-012-3147-x. Pediatr Surg Int. 2012. PMID: 22885732
-
Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.Eur J Pediatr. 2022 Jan;181(1):407-412. doi: 10.1007/s00431-021-04209-6. Epub 2021 Jul 24. Eur J Pediatr. 2022. PMID: 34304300
-
Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.Orphanet J Rare Dis. 2017 Jun 2;12(1):108. doi: 10.1186/s13023-017-0653-x. Orphanet J Rare Dis. 2017. PMID: 28576129 Free PMC article.
-
Non-radioactive Rb+ Efflux Assay for Screening KATP Channel Modulators.Methods Mol Biol. 2024;2796:191-210. doi: 10.1007/978-1-0716-3818-7_12. Methods Mol Biol. 2024. PMID: 38856903
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous